T-cell prolymphocytic leukemia surgery: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 4: | Line 4: | ||
==Surgery== | ==Surgery== | ||
Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission. | [[Autologous]] and [[allogeneic]] [[Stem cell transplant|stem cell transplants]] is the mainstay of [[therapy]] for [[Patient|patients]] who achieve [[Remission (medicine)|remission]]. | ||
==Surgery== | |||
[[Autologous]] and [[allogeneic]] [[Stem cell transplant|stem cell transplants]] is the mainstay of [[therapy]] for [[Patient|patients]] who achieve [[Remission (medicine)|remission]]. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 18:29, 4 April 2019
|
T-cell prolymphocytic leukemia Microchapters |
|
Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
T-cell prolymphocytic leukemia surgery On the Web |
|
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia surgery |
|
Risk calculators and risk factors for T-cell prolymphocytic leukemia surgery |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3]
Surgery
Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission.
Surgery
Autologous and allogeneic stem cell transplants is the mainstay of therapy for patients who achieve remission.